查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1974127

COX-2选择性非类固醇消炎剂（NSAIDs）市场：依给药途径、剂型、产品、适应症、通路和最终用户划分－2026-2032年全球预测

COX-2 Selective NSAIDs Market by Route, Dosage Form, Product, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，COX-2 选择性非类固醇消炎剂(NSAID) 市场价值将达到 86.6 亿美元，到 2026 年将成长至 91.5 亿美元，到 2032 年将达到 127.8 亿美元，年复合成长率为 5.71%。

主要市场统计数据
基准年 2025 86.6亿美元
预计年份：2026年 91.5亿美元
预测年份 2032 127.8亿美元
复合年增长率 (%) 5.71%

对现代医学中选择性 COX-2 抑制剂策略的治疗作用、不断演变的安全性概况和商业性格局进行了权威概述。

自问世以来，选择性COX-2抑制剂占据了独特的治疗领域，它们在提供针对抗发炎和镇痛作用的同时，旨在降低非选择性非类固醇抗发炎药（NSAIDs）相关的胃肠道毒性。其研发和商业化路径受到不断变化的安全性特征、监管要求以及临床实践模式转变的影响。随着临床医生在疗效与心血管和肾臟风险之间寻求平衡，产品差异化越来越侧重于製剂、给药途径和真实世界安全性证据。

简要概述了推动 COX-2 选择性治疗领域结构变化和策略重组的关键临床、商业性和监管因素。

在COX-2选择性非类固醇抗发炎药领域，正在发生多项变革性变化，这些变化正在重新定义研发重点和商业化策略。临床证据的产生不再局限于基础试验，而是更加重视真实世界安全性监测和纵向心血管结局研究，这一转变正在影响药物的采纳决策和处方医生的信心。创新不再局限于新型化合物，而是越来越多地涵盖製剂改进、替代给药系统以及旨在扩大现有药物临床效用并降低安全性风险的联合疗法。

基于证据评估美国在 2025 年实施的关税措施对 COX-2 选择性药物的供应链经济、采购决策和分销韧性的影响。

贸易和关税体系的政策变化会对整个药品供应链产生重大影响。美国在2025年宣布或实施的关税措施为製造商、经销商和医疗保健机构带来了新的考量。针对药品原料药、辅料或成品的关税措施会加剧投入成本的波动，并削弱依赖国际供应商的生产商的利润率稳定性。这项变更促使许多机构重新评估供应商的地理分布，增加关键投入品的库存缓衝，并探索替代物流方案以维持供应的连续性。

对给药途径、剂型、产品系列、适应症、通路和最终用户决策环境等多面向细分因素进行详细解读。

细分市场分析揭示了给药途径、剂型、产品选择、适应症、分销管道和终端用户趋势等因素如何共同塑造选择性COX-2抑制剂疗法的策略重点。基于给药途径，市场分为三个细分市场：注射剂、口服剂和外用剂。这三个观点阐明了临床定位：注射剂适用于急诊护理和手术应用，口服剂适用于慢性门诊治疗，外用剂适用于局部疼痛管理，每种剂型的安全性和依从性特征各不相同。基于剂型，市场分为胶囊剂、悬浮液和锭剂三个细分市场。这些剂型会影响依从性、病人偏好和生产复杂性。速释片或缓释片的设计可能会改变关于给药频率和健保报销的讨论。

实际的区域分析揭示了法规结构、准入趋势和製造地如何在全球市场中创造差异化的机会和风险。

区域趋势持续对COX-2选择性抑制剂的临床应用、法规要求和供应链设计产生重大影响。在美洲，与监管机构和支付方的谈判中，成本效益和真实世界疗效证据备受重视；同时，数位处方笺和网路药局管道的快速普及正在改变患者的用药模式，尤其是在美国市场。鑑于近期贸易政策的变化，北美生产和分销基础设施的韧性日益凸显，相关人员的参与也越来越侧重于透过药物监测数据的透明度和与支付方的合作来衡量疗效。

对製造商和经销商如何利用产品组合创新、证据产生和供应链韧性来保护和扩大其市场地位进行简明策略回顾。

製造商、合约开发商和分销合作伙伴之间的竞争日益取决于产品组合的灵活性、证据产生能力和供应链的成熟度。领先的製药公司和学名药生产商正致力于透过改进製剂、采用缓释技术以及拓展监管管道允许的适应症来优化产品生命週期管理。与契约製造製造商和专业经销商建立策略合作伙伴关係，能够实现注射剂和新型外用製剂的快速大规模生产，而内部研发能力对于维护知识产权相关的製程优势和确保品管仍然至关重要。

一系列优先考虑的可操作建议，旨在加强供应链韧性、产生证据并实现 COX-2 抑制剂的商业性差异化。

产业领导者应采取一系列切实有效的措施，以协调临床价值、营运韧性和商业性可行性。首先，应实现关键中间体和成品供应商网路的多元化，以降低地缘政治因素和关税相关干扰的影响，并透过合约实施保障措施，确保前置作业时间和品质标准。同时，投资双重采购和区域製造方案，将降低单一故障点的风险，并增强对需求波动的应对力。

一个透明且可重复的混合方法研究框架，结合了专家访谈、监管审查、临床文献整合和供应链映射。

本研究方法结合了定性和定量技术，以验证基于多个互补资料流的见解。研究人员首先对临床医生、采购负责人、监管专家和商业负责人进行了结构化访谈，以此作为主要资讯来源，收集有关处方行为、药物采纳标准和供应链限制的实地资讯。其次，研究人员查阅了同行评审文献、监管指导文件、临床试验註册资讯和公共药物监测资料库，以对安全讯号和治疗定位进行三角验证。

简而言之，为了维持选择性 COX-2 抑制剂的可近性和价值，需要强调在临床可靠性与营运和商业性灵活性之间取得平衡。

选择性COX-2抑制剂在疼痛和发炎管理领域仍占据着重要的策略地位，但其未来的发展轨迹并非由单一因素决定，而是取决于安全性证据、供应可靠性、监管预期以及不断变化的给药途径等因素的相互作用。透过优化製剂和给药途径来实现临床差异化，以及严格的真实世界安全性监测，对于维持处方医师的信心至关重要。同时，商业性成功取决于能够应对政策和地缘政治衝击的稳健筹资策略和适应性分销模式。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：COX-2选择性非类固醇消炎剂（NSAID）市场：依给药途径划分

  • 注射药物
  • 口服
  • 外用製剂

第九章：依上市剂型分类的COX-2选择性非类固醇消炎剂（NSAIDs）

  • 胶囊
  • 悬浮液
  • 药片

第十章：COX-2选择性非类固醇消炎剂（NSAIDs）市场：依产品分类

  • 塞来昔布
  • 依曲昔布
  • 罗非昔布
  • 伐地考昔

第十一章：COX-2选择性非类固醇消炎剂（NSAID）市场：依适应症划分

  • 僵直性脊椎炎
  • 骨关节炎
  • 类风湿性关节炎

第十二章：COX-2选择性非类固醇消炎剂（NSAIDs）市场：依通路划分

  • 医院药房
  • 网路药房
    • 厂商直销
    • 第三方电商零售商
  • 零售药房
    • 连锁药局
    • 独立药房

第十三章：COX-2选择性非类固醇消炎剂（NSAIDs）市场：依最终用户划分

  • 诊所
    • 门诊部
    • 专科诊所
  • 居家医疗
  • 医院
    • 私人的
    • 民众

第十四章：COX-2选择性非类固醇消炎剂（NSAID）市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：COX-2选择性非类固醇消炎剂（NSAIDs）市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：COX-2选择性非类固醇消炎剂（NSAID）市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国COX-2选择性非类固醇消炎剂（NSAID）市场

第十八章：中国COX-2选择性非类固醇消炎剂（NSAID）市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
Product Code: MRR-5D340F440BAE

The COX-2 Selective NSAIDs Market was valued at USD 8.66 billion in 2025 and is projected to grow to USD 9.15 billion in 2026, with a CAGR of 5.71%, reaching USD 12.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.66 billion
Estimated Year [2026] USD 9.15 billion
Forecast Year [2032] USD 12.78 billion
CAGR (%) 5.71%

An authoritative overview of the therapeutic role, evolving safety profile, and commercial context shaping selective COX-2 inhibitor strategies in contemporary practice

Selective COX-2 inhibitors have occupied a distinct therapeutic niche since their introduction, offering targeted anti-inflammatory and analgesic effects while aiming to reduce gastrointestinal toxicity associated with non-selective NSAIDs. Their development and commercialization pathways have been shaped by an evolving safety profile, changes in regulatory expectations, and shifting clinical practice patterns. As clinicians balance efficacy against cardiovascular and renal risk considerations, product differentiation increasingly pivots on formulation, route of administration, and real-world safety evidence.

Over the past decade, the landscape has matured from first-generation molecules and market withdrawals to a more cautious, evidence-driven environment where lifecycle management and post-marketing surveillance are critical. Concurrently, digital health tools, telemedicine, and e-pharmacies have altered how patients access prescriptions and adhere to therapy, prompting manufacturers and distributors to rethink engagement models. Patient centricity and prescriber access to comparative effectiveness data now inform adoption decisions as much as pharmacology.

This introduction frames a deeper exploration of market dynamics, regulatory pressures, distribution transformation, and therapeutic competition. The subsequent analysis connects clinical science, supply chain realities, and commercial strategy to inform decision-making for stakeholders operating across routes, dosage forms, and regional markets. It emphasizes the need for integrated approaches that reconcile safety stewardship, formulary positioning, and resilient sourcing in a complex geopolitical and reimbursement environment.

A concise synthesis of the major clinical, commercial, and regulatory forces driving structural change and strategic realignment across the COX-2 selective therapeutic ecosystem

The COX-2 selective NSAIDs landscape is experiencing several transformative shifts that are redefining development priorities and commercialization tactics. Clinical evidence generation has moved beyond pivotal trials to emphasize real-world safety surveillance and longitudinal cardiovascular outcome studies, and this shift has influenced formulary decisions and prescriber confidence. Innovation is no longer limited to new chemical entities; it increasingly encompasses reformulations, alternate delivery systems, and combination approaches that aim to expand the clinical utility of established molecules while mitigating safety concerns.

Concurrently, distribution and access models are being disrupted by digital channels and direct-to-provider supply relationships, which change how patients obtain therapy and how manufacturers manage stocking and replenishment. Supply chain resilience has ascended the strategic agenda, with firms reassessing supplier concentration and geographic risk exposure in response to trade policy volatility and pandemic-era disruptions. Payer scrutiny and value-based contracting are encouraging manufacturers to demonstrate comparative effectiveness and adherence benefits, prompting targeted outcomes research.

Lastly, regulatory expectations are tightening around post-marketing evidence and pharmacovigilance, driving more rigorous safety monitoring and transparent risk communication. These shifts collectively pressure organizations to integrate clinical, commercial, and regulatory strategies, adopt adaptive trial and evidence-generation frameworks, and pursue collaborative partnerships that can accelerate innovation while managing risk.

An evidence-informed appraisal of how the 2025 United States tariff measures altered supply chain economics, sourcing decisions, and distribution resilience for COX-2 selective medicines

Policy shifts in trade and tariff regimes can have material implications across pharmaceutical supply chains, and the United States tariffs announced or implemented in 2025 introduced a new set of considerations for manufacturers, distributors, and healthcare providers. Tariff measures targeting active pharmaceutical ingredients, excipients, or finished goods elevate input cost volatility and erode margin stability for producers that rely on international suppliers. This change has led many organizations to reassess supplier geographies, increase inventory buffers for critical inputs, and explore alternative logistics arrangements to preserve continuity of supply.

Beyond direct cost impacts, tariff-driven uncertainty influences long-term sourcing strategies. Some firms have accelerated nearshoring initiatives or diversified contract manufacturing to higher-resilience partners, while others have engaged in bilateral supplier agreements to lock in pricing and delivery terms. For distributors and pharmacies, especially those with narrow margins, tariff-related cost pressures necessitate renegotiation of procurement contracts and may shorten the window for promotional activity or introduction of new dosage forms.

Clinicians and institutional buyers have responded by emphasizing predictable supply and consistent clinical performance; procurement teams now factor geopolitical risk into tender evaluations and formulary decisions. Regulatory compliance and customs complexity have also increased administrative burdens, requiring enhanced trade compliance capabilities. While these measures do not change the underlying clinical value of selective COX-2 therapies, they influence pricing strategies, supplier selection, and operational investments that ultimately affect availability and patient access across care settings.

A detailed, multi-dimensional interpretation of segmentation drivers spanning routes, dosage forms, product portfolios, indications, channels, and end-user decision contexts

Segment-level insights reveal how route, dosage form, product selection, indication, distribution channel, and end-user dynamics together shape strategic priorities for selective COX-2 therapies. Based on Route, market is studied across Injectable, Oral, and Topical and this tripartite lens clarifies clinical positioning: injectables are often aligned with acute care settings and procedural use, oral forms support chronic outpatient treatment, and topical preparations address localized pain management with a different safety and adherence profile. Based on Dosage Form, market is studied across Capsule, Suspension, and Tablet which influences adherence characteristics, patient preference, and manufacturing complexity; fast-dissolving or extended-release tablet designs can alter dosing frequency and reimbursement discussions.

Product-level differentiation persists and is informed by pharmacology and legacy safety records; based on Product, market is studied across Celecoxib, Etoricoxib, Rofecoxib, and Valdecoxib and each molecule carries unique regulatory histories and perceived risk-benefit narratives that affect clinical uptake and formulary status. Indication-driven demand patterns are significant; based on Indication, market is studied across Ankylosing Spondylitis, Osteoarthritis, and Rheumatoid Arthritis and each condition presents different treatment paradigms, concomitant therapy considerations, and payer expectations regarding long-term safety monitoring.

Distribution and access analyses underscore channel-specific imperatives; based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Online Pharmacy is further studied across Direct Manufacturer and Third-Party ERetailers and the Retail Pharmacy is further studied across Chain Pharmacy and Independent Pharmacy. These distinctions matter for inventory velocity, promotional strategy, and patient support programs. Finally, stakeholder segmentation by end use clarifies procurement and clinical decision-making; based on End User, market is studied across Clinics, Homecare, and Hospitals. The Clinics is further studied across Outpatient Clinics and Specialty Clinics and the Hospitals is further studied across Private and Public and each subsegment exerts distinct influence over purchasing cycles, tendering behavior, and expectations for clinical support materials. Integrated strategies that reflect this multi-dimensional segmentation are required to match product profiles with clinical settings, payer mandates, and patient preferences.

A pragmatic regional analysis describing how regulatory frameworks, access dynamics, and manufacturing footprints create differentiated opportunities and risks across global markets

Regional dynamics continue to exert a profound influence on clinical adoption, regulatory requirements, and supply chain design for COX-2 selective therapies. In the Americas, regulatory pathways and payer negotiations emphasize cost-effectiveness and real-world outcome evidence, while the U.S. market in particular demonstrates rapid uptake of digital prescribing and e-pharmacy channels that alter patient access patterns. North American manufacturing and distribution infrastructures are increasingly assessed for resilience in light of recent trade policy shifts, and stakeholder engagement frequently centers on pharmacovigilance data transparency and payer-aligned outcome measures.

Europe, Middle East & Africa presents a heterogeneous environment where regulatory harmonization across certain jurisdictions contrasts with localized approval and reimbursement practices in others. Clinicians in several European markets prioritize long-term safety data and head-to-head comparative studies, which can slow adoption in the absence of robust evidence. Meanwhile, pockets of the Middle East and Africa emphasize access and supply stability, prompting distributors to pursue secured contracts and regional warehousing to reduce stockouts and ensure consistent patient access.

In Asia-Pacific, rapid demographic shifts and expanding primary care capacity are driving notable demand for convenient oral and topical therapies. The region also hosts a growing manufacturing base for APIs and finished products, creating both competitive sourcing opportunities and regulatory complexity for exporters. Evolving digital health ecosystems in several Asia-Pacific markets are also reshaping patient engagement and pharmacy fulfillment practices. Across all regions, variability in reimbursement frameworks, clinician guidelines, and supplier networks requires tailored market entry and commercialization strategies that align with local healthcare delivery models and regulatory expectations.

A compact strategic review of how manufacturers and distributors are leveraging portfolio innovation, evidence generation, and supply resilience to defend and expand their foothold

Competitive dynamics among manufacturers, contract developers, and distribution partners are increasingly defined by portfolio agility, evidence-generation capabilities, and supply chain sophistication. Leading pharmaceutical firms and generics manufacturers are focusing on lifecycle management through formulation upgrades, extended-release technologies, and indication expansion where regulatory pathways permit. Strategic partnerships with contract manufacturers and specialty distributors enable rapid scale-up for injectables or novel topical formats, while in-house capabilities remain critical for preserving IP-related process advantages and ensuring quality control.

Market entrants and incumbents alike are investing in real-world evidence platforms to differentiate products on safety and adherence metrics, which supports negotiation with payers and hospital formularies. Commercial differentiation is often achieved through patient support programs that bolster adherence for chronic indications and through provider education initiatives that emphasize appropriate risk mitigation strategies. On the distribution side, an increasing number of companies are optimizing omnichannel strategies that integrate hospital procurement, retail pharmacy relationships, and direct-to-patient online fulfillment to minimize friction across the patient journey.

Finally, corporate strategies include targeted M&A to secure API capacity, selective licensing to widen product reach, and co-development agreements to accelerate access in markets with high regulatory complexity. Firms that combine manufacturing resilience, a clear evidence-generation roadmap, and channel-specific commercialization approaches are best positioned to navigate safety sensitivities while sustaining competitive advantage.

A concise set of prioritized, implementable recommendations designed to fortify supply resilience, evidence generation, and commercial differentiation for COX-2 therapies

Industry leaders should adopt a set of pragmatic, high-impact actions that align clinical value with operational resilience and commercial execution. First, diversify supplier networks for critical intermediates and finished goods to mitigate geopolitical and tariff-related disruptions, while implementing contractual safeguards that lock in lead times and quality standards. Parallel investments in dual-sourcing and regional manufacturing options will reduce exposure to single-point failures and enhance responsiveness to demand shifts.

Second, prioritize evidence strategies that combine randomized trial data with robust real-world outcomes and pharmacovigilance programs to address safety concerns and support favorable formulary placement. Third, accelerate development of differentiated formulations and delivery systems-such as topical preparations with reduced systemic exposure or oral formulations that improve adherence-to strengthen clinical positioning and reimbursement negotiations. Fourth, deepen engagement with payers and large institutional buyers through value-based contracting pilots and outcome-linked agreements that align reimbursement with demonstrated patient benefit.

Finally, modernize commercial operations by integrating digital channels into the sales mix, tailoring messaging to channel-specific stakeholders, and investing in provider education that clarifies appropriate patient selection and risk mitigation. Taken together, these recommendations reduce supply and regulatory risk while creating defensible clinical and commercial differentiation that supports long-term sustainability.

A transparent and replicable mixed-methods research framework combining expert interviews, regulatory review, clinical literature synthesis, and supply chain mapping

The underlying research approach combines qualitative and quantitative techniques to ensure findings are grounded in multiple, corroborating data streams. Primary inputs included structured interviews with clinicians, procurement officers, regulatory specialists, and commercial leaders to capture frontline insights on prescribing behavior, formulary decision criteria, and supply chain constraints. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public pharmacovigilance databases to triangulate safety signals and therapeutic positioning.

Operational analyses relied on supply chain mapping and trade flow assessments to evaluate sourcing concentration and logistics vulnerabilities, supplemented by a review of recent policy changes and tariff announcements that could affect cost structures and lead times. Channel-level dynamics were informed by pharmacy dispensing trends and e-pharmacy adoption studies, while end-user perspectives were validated through stakeholder workshops and scenario testing. Throughout the project, findings were iteratively validated with subject-matter experts to refine assumptions and ensure practical relevance.

The methodology emphasizes transparency in source selection and analytical assumptions, and includes appendices that document interview protocols, search strategies, and criteria for inclusion of clinical and regulatory materials. This mixed-methods approach supports robust conclusions about strategic imperatives without relying on proprietary third-party estimates, and it enables replication of key analytical steps by informed stakeholders.

A succinct conclusion emphasizing the imperative to pair clinical credibility with operational and commercial agility to preserve access and value for selective COX-2 therapies

Selective COX-2 inhibitors remain strategically significant within pain and inflammation management, but their future trajectory is determined less by a single factor than by the interplay among safety evidence, supply reliability, regulatory expectations, and evolving access channels. Clinical differentiation through formulation and route optimization, together with rigorous real-world safety monitoring, will be central to maintaining prescriber confidence. At the same time, commercial success depends on resilient sourcing strategies and adaptive distribution models that can absorb policy and geopolitical shocks.

Organizations that invest in both clinical evidence and operational robustness will be better positioned to secure favorable formulary outcomes and to respond to payer demands for demonstrable value. The confluence of digital channel growth, heightened payer scrutiny, and tariff-induced cost pressures creates both risks and opportunities: firms that act decisively on diversification, evidence generation, and targeted patient support will convert complexity into competitive advantage. The conclusion is clear: aligning clinical credibility with supply chain and commercial agility is essential to sustaining long-term access and value for selective COX-2 therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COX-2 Selective NSAIDs Market, by Route

  • 8.1. Injectable
  • 8.2. Oral
  • 8.3. Topical

9. COX-2 Selective NSAIDs Market, by Dosage Form

  • 9.1. Capsule
  • 9.2. Suspension
  • 9.3. Tablet

10. COX-2 Selective NSAIDs Market, by Product

  • 10.1. Celecoxib
  • 10.2. Etoricoxib
  • 10.3. Rofecoxib
  • 10.4. Valdecoxib

11. COX-2 Selective NSAIDs Market, by Indication

  • 11.1. Ankylosing Spondylitis
  • 11.2. Osteoarthritis
  • 11.3. Rheumatoid Arthritis

12. COX-2 Selective NSAIDs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
    • 12.2.1. Direct Manufacturer
    • 12.2.2. Third-Party ERetailers
  • 12.3. Retail Pharmacy
    • 12.3.1. Chain Pharmacy
    • 12.3.2. Independent Pharmacy

13. COX-2 Selective NSAIDs Market, by End User

  • 13.1. Clinics
    • 13.1.1. Outpatient Clinics
    • 13.1.2. Specialty Clinics
  • 13.2. Homecare
  • 13.3. Hospitals
    • 13.3.1. Private
    • 13.3.2. Public

14. COX-2 Selective NSAIDs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. COX-2 Selective NSAIDs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. COX-2 Selective NSAIDs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States COX-2 Selective NSAIDs Market

18. China COX-2 Selective NSAIDs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. AstraZeneca PLC
  • 19.7. Bayer AG
  • 19.8. Bristol-Myers Squibb Company
  • 19.9. Eli Lilly and Company
  • 19.10. GlaxoSmithKline plc
  • 19.11. Johnson & Johnson
  • 19.12. Merck & Co. Inc.
  • 19.13. Novartis AG
  • 19.14. Pfizer Inc.
  • 19.15. Roche Holding AG
  • 19.16. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COX-2 SELECTIVE NSAIDS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CELECOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CELECOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CELECOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ETORICOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ETORICOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ETORICOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROFECOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROFECOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROFECOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY VALDECOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY VALDECOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY VALDECOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DIRECT MANUFACTURER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DIRECT MANUFACTURER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DIRECT MANUFACTURER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY THIRD-PARTY ERETAILERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY THIRD-PARTY ERETAILERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY THIRD-PARTY ERETAILERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 197. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 198. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 230. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 231. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 241. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 242. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 246. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROUTE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)